Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.57 |
| ▸ | Q9HBH1 | 1/20 | 0.31 | |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24574423 | 0.89 | TUBB1 (0.46) | TUBB1 | |
| SCHEMBL24575110 | 0.89 | TUBB1 (0.47) | TUBB1 | |
| SCHEMBL26606699 | 0.86 | TUBB1 (0.61) | TUBB1PDF | |
| SCHEMBL24360627 | 0.84 | TUBB1 (0.70) | TUBB1PDF | |
| SCHEMBL22308454 | 0.83 | TUBB1 (0.43) | TUBB1 | |
| SCHEMBL58040 | 0.82 | TUBB1 (0.66) | TUBB1PDF | |
| SCHEMBL14567801 | 0.82 | TUBB1 (0.66) | TUBB1PDF | |
| SCHEMBL13660110 | 0.82 | TUBB1 (0.66) | TUBB1PDF | |
| SCHEMBL58085 | 0.82 | TUBB1 (0.74) | TUBB1PDF | |
| SCHEMBL13660108 | 0.82 | TUBB1 (0.74) | TUBB1PDF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220202948-A1 | Agent for Eliminating Pluripotent Stem Cells | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-06-30 | — | — | US | disclosed |
| US-20220144889-A1 | Hemiasterlin Derivative Having Cysteine Residue | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-05-12 | — | — | US | disclosed |
| US-20220125941-A1 | Hemiasterlin Derivative and Antibody-Drug Conjugate Thereof | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-04-28 | — | — | US | disclosed |
| US-20200247847-A1 | Antibody-Drug Conjugates Including Hemiasterlin Derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144889-A1 | Hemiasterlin Derivative Having Cysteine Residue | SHBG, CYP11A1, CYP11B1 | TUBB1 1472/4885PDF 1478/4885 |
| US-20220202948-A1 | Agent for Eliminating Pluripotent Stem Cells | POU5F1, POU2F1, POU2F2 | TUBB1 119/4885PDF 4784/4885 |
| US-20200247847-A1 | Antibody-Drug Conjugates Including Hemiasterlin Derivative | HSD3B2, HSD3B1, HSD11B2 | TUBB1 624/4885PDF 3611/4885 |
| US-20220125941-A1 | Hemiasterlin Derivative and Antibody-Drug Conjugate Thereof | SHBG, HSD17B7, CYP17A1 | TUBB1 802/4885PDF 3740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.